Inflammatory Bowel Disease Treatment Market size was valued at USD 23.26 billion in 2024 and is likely to exceed USD 60.79 billion by the end of 2037, registering over 7.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of inflammatory bowel disease treatment is evaluated at USD 24.69 billion.
The growth of the market can be attributed to the increasing number of inflammatory bowel diseases, including fecal incontinence, diarrhea, and constipation, across the world. As per the World Health Organization, the second most common cause of death in children under the age of five is diarrhea. Around 525 000 children under five dies from diarrhea each year. Every year, there are around 1.7 billion cases of pediatric diarrheal illness worldwide.
Global IBD treatment market trends such as, higher number of people with inflammatory intestine disease backed by the approval of new biologic drugs for IBD. Hence, the development of novel drugs is anticipated to hike the market growth over the forecast period. It was found that in contrast to the typical review process, which takes 10 months, FDA intends to act on an application within 6 months. Additionally, the rise in demand for IBD treatment in developing nations is also one of the major factors that are predicted to drive the global market for IBD treatments over the forecast period. Drugs that would considerably improve the treatment, diagnosis, or prevention of critical illnesses are given a priority review classification, which focuses attention and resources on their evaluation.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.6% |
|
Base Year Market Size (2024) |
USD 23.26 billion |
|
Forecast Year Market Size (2037) |
USD 60.79 billion |
|
Regional Scope |
|
Disease Indication (Ulcerative Colitis and Crohn’s Disease)
The inflammatory bowel disease treatment market is segmented and analyzed for demand and supply by disease indication into ulcerative colitis and Crohn’s disease. Out of these types of segments, the crohn’s disease segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing instances of crohn’s diseases compared to ulcerative colitis worldwide, backed by the launch of several healthcare program for early diagnosis and treatment of the disease. For instance, it was noticed that nearly 10 out of 100,000 people across the globe are diagnosed with crohn’s disease every year which sums up to approximate 30,000 new cases of the disease annually.
Distribution Channel (Hospital, Retail, and Online Pharmacies)
The global IBD treatment market is also segmented and analyzed for demand and supply by distribution channel into hospital, retail, and online pharmacies. Amongst these segments, the hospital segment is expected to garner a significant share. The growth of the segment can be ascribed to the rising patient flow in the hospitals and increasing spending on healthcare across the globe as a result of doctors' increasing caution and suggestions of tests for the parents. As per the health expenditure report, global health spending has increased overall during the previous 20 years, doubling in real terms, reaching USD 8.5 trillion in 2019 and 9.8% of GDP (up from 8.5% in 2000).
Our in-depth analysis of the global market includes the following segments:
|
By Drug Class |
|
|
By Disease Indication |
|
|
By Distribution Channel |
|
North American Market Forecast
The North America IBD treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037. The growth of the market can be attributed majorly to the U.S. and Canada's high prevalence and rising incidence of ulcerative colitis and Crohn's disease, as well as their developed healthcare systems and high risk of lifestyle-related variables. It was found during research that IBD, which includes Crohn's disease and ulcerative colitis, has been identified in an estimated 3.1 million individuals (1%) in the United States, out of which, around 1 million of them were males and remaining was stated to be female. The prevalence of IBD can differ based on the several factors, such as, age, race, sociodemographic characteristics, education, and economic conditions. A report published by Centers for Disease Control and Prevention stated that the instances of IBD rise from 2001 to 2018 among all ethnicity groups, especially in non-Hispanic Black adults in the region. Furthermore, growing awareness of inflammatory bowel disease (IBD) in the region, supported by educational advancement and growth in the number of government initiatives are estimated to enlarge the inflammatory bowel disease treatment market size in North America by triggering the prevalence of early diagnosis. For instance, approximately 25 million Medicare fee-for-service beneficiaries aged above 65 went through the diagnosis procedure of Crohn’s disease or ulcerative colitis in the region in 2018.
The Bristol-Myers Squibb Company to announce that Zeposia (ozanimod) has been given marketing authorization by the European Commission for the treatment of individuals with moderately to highly active ulcerative colitis. Zeposia is orally administered and recommended to be taken once a day. It is the only oral S1P receptor modulator and first innovative method to cure this chronic immune-mediated disease with high efficiency.
Bausch Health Companies Inc.- Salix (a subsidiary of Bausch Health Companies Inc.) and Mitsubishi Tanabe Pharma have an exclusive license agreement for the development and marketing of a late-stage investigational S1P modulator for the treatment of inflammatory bowel disease.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?